THALES
7.10.2019 07:47:05 CEST | Business Wire | Press release
Powered by the cutting-edge technologies and products of Thales and Verint, the two companies are pleased to present The Cyberthreat Handbook , a report of unprecedented scope designed to provide a classification and basis for further investigation of major groups of cyberattackers, including cybercriminals, cyberterrorists, hacktivist groups and state-sponsored hackers. As part of the strategic partnership to create a comprehensive, state-of-the art Cyber Threat Intelligence technologies, threat intelligence analysts from Thales and Verint have worked together to provide this unique 360° view of the cyberthreat landscape, with detailed descriptions of the activities of about sixty particularly significant groups, including their tactics and techniques, their motives and the sectors targeted from analysis of multiple data sources such as web and threat intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191006005044/en/
As cybersecurity grows in importance, Thales and Verint have worked together to find out more about cyberattackers and the techniques they employ, the purpose being to help organisations in the private and public sectors to better detect and anticipate future attacks. The cyberthreat landscape is extremely diversified, and knowing one's enemies can be particularly complex in this world of subterfuge and deception.
"The Thales and Verint teams are immensely proud to release this report today as part of its technology and domain expertise cooperation. Unique in its breadth and depth, it is the culmination of many months of research, investigation and painstaking analysis and correlation of relevant data. As cyberthreats proliferate and evolve, cybersecurity clearly has a major role to play, particularly for critical infrastructure providers. It is our duty to analyse, understand and describe the techniques employed by cyberattackers so that our customers and all other businesses and organisations are better prepared to detect and anticipate future attacks." Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales
“Joining forces with Thales strengthens our mutual ability to deliver comprehensive knowledge of potential threats, and thus provide the necessary cyber security protection,” said Elad Sharon, President, Verint Cyber Intelligence Solutions. “Verint Cyber Intelligence leverages years of intelligence domain expertise, embedded within investigation methodologies and technologies critical to prevent cyber-attacks before they get into the gateway of the organization. This report generates unique insights and knowldege to cyber and security experts to mitigate and foresee cyberattacks”.
Analysts from Thales and Verint have defined four major categories of attackers based on their motives and ultimate objectives. Out of approximately sixty major groups of attackers analysed, 49% are state-sponsored groups often aiming to steal sensitive data from targets of geopolitical interest. 26% are ideologically motivated hacktivists, closely followed by cybercriminals (20%) who are driven by financial gain. In fourth position, cyberterrorists account for 5% of the groups analysed.
All the world's major economic, political and military powers are priority targets of cyberattackers. The 12 countries in the world with the highest GDP are all at the top of the list of targets, headed by the United States, Russia, the European Union (particularly the United Kingdom, France and Germany) and China, followed by India, South Korea and Japan.
The sectors most targeted by these major attacks are States and their defence capabilities, followed by the financial sector, energy and transportation. Attacks towards medias and health industry are increasing fast.
Last but not least, a growing number of groups of attackers are now focusing on vulnerabilities in the supply chain, and in particular on smaller partners, suppliers and service providers that are used as trojans to access major targets.
Notes to editors - Methodology This report does not set out to be an exhaustive inventory of cyberattackers but rather to shed light on the major groups of attackers that have been identified over the last 10 years. The sixty-odd groups and 490 attack campaigns analysed in the report were selected because they are considered emblematic in terms of their impact, attack techniques, scope, target profiles, historical nature or recent emergence. The entire analysis is based on the MITRE Att&ck matrix , a knowledge base of adversary tactics and techniques. More details can be found in the press kit.
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments
About Verint Systems Inc. Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimisation, security intelligence, and fraud, risk and compliance. Today, over 10,000 organisations in more than 180 countries—including over 80 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence® at www.verint.com .
About Verint Cyber Intelligence. Verint Cyber Intelligence is a leading global provider of security and intelligence data mining software. Our broad and deep product portfolio is deployed in over 100 countries, helping government, critical infrastructure and enterprise organizations to neutralize and prevent terror, crime and cyber threats for a safer world. |
PLEASE VISIT
Thales Group
Download photos
Download the report
View source version on businesswire.com: https://www.businesswire.com/news/home/20191006005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
